About Eukaryotic translation initiation factor 2 subunit 1
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) is a protein
from Homo sapiens identified by UniProt accession
P05198, 315 residues long.
MolForge cross-references it against 0 known binders and
138 disease associations.
Target properties
| Protein name | Eukaryotic translation initiation factor 2 subunit 1 |
| UniProt accession | P05198 |
| Gene | EIF2S1 |
| Organism | Homo sapiens |
| Length | 315 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (138)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.33
- appendicular lean mass · score 0.12
- hyperinsulinism due to INSR deficiency · score 0.05
- MODY · score 0.05
- exercise-induced hyperinsulinism · score 0.05
- hyperinsulinism due to glucokinase deficiency · score 0.05
- reticulocyte count · score 0.05
- hypoinsulinemic hypoglycemia and body hemihypertrophy · score 0.05
- unipolar depression · score 0.05
- hyperinsulinism-hyperammonemia syndrome · score 0.04
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P05198-F1 | alphafold | PREDICTED | 77.82 | — |
Amino-acid sequence (315 residues)
MPGLSCRFYQ HKFPEVEDVV MVNVRSIAEM GAYVSLLEYN NIEGMILLSE LSRRRIRSIN KLIRIGRNEC VVVIRVDKEK GYIDLSKRRV SPEEAIKCED KFTKSKTVYS ILRHVAEVLE YTKDEQLESL FQRTAWVFDD KYKRPGYGAY DAFKHAVSDP SILDSLDLNE DEREVLINNI NRRLTPQAVK IRADIEVACY GYEGIDAVKE ALRAGLNCST ENMPIKINLI APPRYVMTTT TLERTEGLSV LSQAMAVIKE KIEEKRGVFN VQMEPKVVTD TDETELARQM ERLERENAEV DGDDDAEEME AKAED
Explore Eukaryotic translation initiation factor 2 subunit 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets